Following the recent publication of clinical trial data showing Ivermectin solution to be a safe and effective pediculicide, two further recent items of note:

A recently-published study has found high occurrance of a genetic mutation in a lice sample which correlates with resistance to permethrin and malathion treatments.

A recently published study has found that ivermectin solution has strong in vivo pediculicide properties.

A petition requesting that lindane be withdrawn from sale as a second-line pediculicide has been denied by the US Food and Drug Administration (FDA).

An assessment and author response to a 2009 clinical trial of spinosad has been published in Archives of Dermatology.

A clinical trial has been registered researching the possibility of using a novel pediculicide to prevent, rather than remove, head lice infection.

A new study has shown that Ivermectin lotion is effective when applied topically to treat head lice infection.

A new study has been published investigating the effectiveness of a combination of isopropyl myristate and cyclomethicone D5 in head lice treatment via a non-traditional physical mechanism of action, thus avoiding issues of genetic resistance to treatment.

A new article in the Journal of Paediatric Health Care reviews recent pediculosis treatment developments and offers recommendations for the best methods of treatment.

The US Food and Drug Administration (FDA) is introducing new requirements and responsibilities for the registration and listing of Medical Devices, effective October 1, 2012.